01
Low NADAC$0.030
→
Avg plan cost$0.063
Part D spend $257.1M
2× spread, current vs floor
6 molecules in this class, $266.7M combined CY2024 Part D spend across 21.5M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.
Every drug in the Histamine-2 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.